Bayesian Capital Management, LP Veracyte, Inc. Transaction History

Bayesian Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$22.33 - $29.92 $189,805 - $254,320	-8,500 Reduced 31.38%	18,591 $415,000
Q2 2023 Aug 14, 2023	SELL	$20.96 - $26.99 $232,656 - $299,589	-11,100 Reduced 29.06%	27,091 $690,000
Q1 2023 May 15, 2023	BUY	$20.58 - $27.89 $550,453 - $745,973	26,747 Added 233.72%	38,191 $851,000
Q4 2022 Feb 14, 2023	BUY	$15.31 - $29.94 $175,207 - $342,633	11,444 New	11,444 $271,000
Q2 2022 Aug 15, 2022	SELL	$15.45 - $29.52 $234,840 - $448,704	-15,200 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$21.94 - $42.51 $333,488 - $646,152	15,200 New	15,200 $419,000
Q2 2021 Aug 13, 2021	SELL	$32.94 - $56.62 $125,171 - $215,156	-3,800 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$44.47 - $81.38 $168,986 - $309,244	3,800 New	3,800 $204,000
Q2 2019 Aug 13, 2019	SELL	$22.1 - $28.56 $250,260 - $323,413	-11,324 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$12.0 - $25.76 $38,400 - $82,432	-3,200 Reduced 22.03%	11,324 $283,000
Q4 2018 Feb 13, 2019	BUY	$9.15 - $14.85 $132,894 - $215,681	14,524 New	14,524 $183,000

307

81.6M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.97B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.